Skip to main content
. Author manuscript; available in PMC: 2010 Nov 30.
Published in final edited form as: J Neuroimmunol. 2009 Oct 8;216(1-2):66–75. doi: 10.1016/j.jneuroim.2009.09.009

Fig. 3.

Fig. 3

CCL11 immunoreactivity in control or axotomized wild-type (WT) and presymptomatic mutant superoxide dismutase 1 (mSOD1) mouse facial motor nucleus 7, 14 and 30 days post-axotomy (DPA). (A) High-power (original magnification, 600×) photomicrographs of CCL11 immunoreactivity in control and axotomized mouse facial motor nucleus. Tailed and untailed arrows indicate CCL11+ FMN and astrocytes, respectively. (B) The average number of CCL11+ FMN in the control and axotomized WT (black bars) and mSOD1 (open bars) mouse facial motor nucleus (±SEM). (C) The average number of CCL11+ astrocytes in the control and axotomized WT (black bars) and mSOD1 (open bars) mouse facial motor nucleus (±SEM). * and # denote significant differences from WT control and mSOD1 control mice at p ≤0.05, respectively. † denotes significant differences from WT 30 DPA mice at p ≤ 0.05.